Dihydroquercetin alleviates dopamine neuron loss via regulating TREM2 activation

Rong Yang1, Dai-di Li1, Xiao-Xian Li1

  • 1Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province and Laboratory Animal Centre, Zunyi Medical University, Zunyi, Guizhou, China.

Abstract

Insights

Dihydroquercetin (DHQ) protects dopamine neurons in Parkinson's disease by activating the TREM2 receptor on microglia, reducing neuroinflammation and neuronal loss. This mechanism is crucial for DHQ's neuroprotective effects.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Immunology

Background:

  • Parkinson's disease (PD) involves dopamine neuron degeneration and neuroinflammation.
  • Microglia-mediated neuroinflammation is a key factor in PD pathogenesis.
  • Triggering receptor expressed on myeloid cells 2 (TREM2) is a potential therapeutic target for suppressing neuroinflammation in PD.

Purpose of the Study:

  • To investigate the neuroprotective mechanisms of dihydroquercetin (DHQ) in Parkinson's disease.
  • To determine if DHQ's neuroprotection is mediated by TREM2 signaling in microglia.

Main Methods:

  • Utilized rat models with induced dopamine neuron damage (LPS, 6-OHDA) to test DHQ.
  • Employed neuronal (MN9D) and microglial (BV2) cell lines to study TREM2 function.
  • Used TREM2 knockout mice to confirm TREM2-dependent effects of DHQ.

Main Results:

  • DHQ protected dopamine neurons and inhibited neuroinflammation induced by LPS and 6-OHDA.
  • DHQ activated microglial TREM2 signaling.
  • DHQ's neuroprotective effects and reduction of inflammatory cytokines were abolished upon TREM2 silencing or in TREM2 knockout mice.

Conclusions:

  • DHQ exerts neuroprotection in Parkinson's disease models.
  • DHQ's mechanism involves the regulation of microglial TREM2 activation.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.2K